<DOC>
	<DOC>NCT00095056</DOC>
	<brief_summary>The purpose of this study is to determine the safety and tolerability of an investigational drug in patients with Type 2 Diabetes Mellitus (a specific type of diabetes) and Chronic Renal Insufficiency (inadequate kidney function).</brief_summary>
	<brief_title>An Investigational Drug in Patients With Type 2 Diabetes Mellitus and Chronic Renal Insufficiency (0431-028)(COMPLETED)</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>Renal Insufficiency, Chronic</mesh_term>
	<mesh_term>Sitagliptin Phosphate</mesh_term>
	<mesh_term>Glipizide</mesh_term>
	<criteria>Patients who are at least 18 years of age diagnosed with type 2 diabetes mellitus (T2DM) (a specific type of diabetes). Patient has renal (kidney) insufficiency (inadequate kidney function) Patient has had heart problems (such as a heart attack or chest pain) or stroke within the past 6 months or any condition or therapy which, in the opinion of the investigator, may not be in the patient's best interest to participate. Pregnant or breast feeding</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>Type 2 Diabetes Mellitus and Chronic Renal Insufficiency</keyword>
</DOC>